Incyte (INCY) FY2025 Earnings Quality Report

Grade: A — Strong Financial Health

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-10) + Yahoo Finance

Auditor: Ernst & Young LLP — Clean opinion (1 critical audit matter: Medicaid Drug Rebate Program allowances)

One-line verdict: Incyte earns an A by clearing seventeen of eighteen checks — the only flag is a watch on inventory growth (71.7%) outpacing COGS growth (19.2%), which directly reflects stockpiling ahead of NIKTIMVO and ZYNYZ launches. FY2025 revenue grew 21.2% to $5.14B, net income jumped from $32.6M to $1.29B as the one-time legacy charges faded, free cash flow hit $1.33B, and the balance sheet is essentially debt-free with $3.58B in cash and $0.04B in debt. M-Score at -2.43 and Z-Score at 8.05 both land in safe territory. The central risk is not financial quality — it is the 2028 JAKAFI patent cliff, which the 10-K discusses as the first-listed risk factor.

The JAKAFI Franchise and the Path Beyond

From the 10-K: "Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. Our global headquarters is located in Wilmington, Delaware, where we conduct discovery, clinical development and commercial operations. We also conduct clinical development and commercial operations from our European headquarters in Morges, Switzerland."

Incyte focuses on three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity (IAI). FY2025 total revenue of $5,141.2M broke down as follows per the MD&A:

JAKAFI remains the core franchise at 60% of total revenue and 71% of product revenue. OPZELURA grew 33.5% driven by atopic dermatitis and vitiligo demand. NIKTIMVO (approved first quarter of 2025) and ZYNYZ (anal carcinoma approval in Q2) are the launch stories — from the MD&A: "NIKTIMVO net product revenues for 2025 reflect continued strong uptake of the product following its commercial launch during the first quarter of 2025. The increase in ZYNYZ net product revenues from 2024 to 2025 was primarily driven by the approval of the product in squamous cell anal carcinoma in the second quarter of 2025."

From the 10-K MD&A: "We recorded net income for the years ended December 31, 2025 and 2024 of $1,286.7 million and $32.6 million, respectively." FY2024 net income of just $32.6M reflects the absorption of one-time charges including in-process R&D writedowns associated with collaboration agreements. The gross margin of 92.8% is essentially flat YoY — an indicator of disciplined pricing across a growing portfolio.

Cash Flow: Reconciling Revenue Growth With Cash Generation

CFFO jumped from $0.34B in FY2024 to $1.41B in FY2025, a 321% increase. The FY2024-to-FY2025 transformation is dramatic but it makes sense: net income swung from $32.6M to $1.29B as one-time charges rolled off, and working capital absorbed less cash relative to the revenue jump. FCF/NI of 1.03 shows that essentially every dollar of reported profit converts to cash — an unusually clean profile for a commercial-stage biotech.

The 18-Point Screening

Revenue Quality

All three revenue-quality checks pass. DSO is flat at 73 days (the typical 2-3 month pharma wholesale cycle), AR grew in line with revenue, and CFFO grew 15x faster than revenue as the net income denominator normalized.

Expense Quality

B1 is the sole watch: inventory grew from $0.06B to $0.10B (+71.7%) while COGS only grew 19.2%. This is directly attributable to the launches of NIKTIMVO and ZYNYZ. With two new commercial products ramping, Incyte built finished-goods inventory in advance. The absolute amounts are small ($40M increment) and the gross margin held flat at 92.8% — so this is a benign stockpiling pattern rather than an inventory obsolescence warning.

Cash Flow Quality

C4 is the most comfortable check: Incyte has $3.58B in cash and short-term investments against essentially zero total debt ($40M). This is a pristine balance sheet.

Balance Sheet

Goodwill of $0.13B and intangibles of $0.12B = $0.25B total, or just 5% of the $5.17B equity base. Incyte has grown organically rather than through acquisitions — a structural reason the balance sheet stays clean.

M&A Risk

Beneish M-Score

M-Score of -2.43 sits below the -2.22 manipulation threshold.

Key Risks from Item 1A

1. Dependence on JAKAFI and the 2028 patent cliff (the first-listed risk factor). From the 10-K: "We depend heavily on our lead product, JAKAFI (ruxolitinib), which is marketed as JAKAVI outside the United States. If we are unable to maintain revenues from JAKAFI or those revenues decrease, our business may be materially harmed. JAKAFI is the first product marketed by us to be approved for sale in the United States. While we also sell our and our licensors' other approved products ICLUSIG, PEMAZYRE, MONJUVI/MINJUVI, OPZELURA, ZYNYZ and NIKTIMVO... we anticipate that JAKAFI product sales will continue to contribute a significant percentage of our total revenues over the next several years. However, we expect that JAKAFI product sales will begin to decline upon the expiration of our patent exclusivity in 2028."

The 10-K lists numerous factors influencing JAKAFI's continued success: "the number of patients diagnosed with intermediate or high-risk myelofibrosis, uncontrolled polycythemia vera or steroid-refractory graft-versus-host disease...the acceptance of JAKAFI by patients and the healthcare community; whether physicians, patients and healthcare payors view JAKAFI as therapeutically effective and safe relative to cost and any alternative therapies."

2. Reimbursement and pricing pressure. From the 10-K: "If we are unable to obtain, or maintain at anticipated levels, coverage and reimbursement for our products from government health administration authorities, private health insurers and other organizations, our pricing may be affected and our product sales, results of operations and financial condition could be harmed. Our ability to commercialize our current and any future approved products successfully will depend in part on the prices we are able to charge for these products and the extent to which adequate coverage and reimbursement levels for the cost of our products and related treatment are obtained from third-party payors."

3. Medicaid Drug Rebate Program estimation (the critical audit matter). From EY's opinion: "As discussed in Note 1 to the consolidated financial statements, the Company recognizes revenues for product received by its customers net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and government rebates. Liabilities related to sales allowances are presented within accrued and other current liabilities on the consolidated balance sheet and totaled $642.5 million as of December 31, 2025."

From the MD&A: "As of December 31, 2025, a 5% change in our sales allowance and accruals would have had an approximate $103.8 million impact on our income before taxes." This is a meaningful sensitivity — roughly 8% of reported net income moves with a 5% swing in rebate estimates.

4. Dependence on new product approvals and collaborations. The 10-K emphasizes the need to commercialize new products to offset JAKAFI. OPZELURA, NIKTIMVO and ZYNYZ are the three key near-term growth drivers but each carries its own regulatory, reimbursement and clinical risk.

Altman Z-Score and F-Score

Z-Score of 8.05 is among the highest in the healthcare set. F-Score of 0.24 translates to a misstatement probability of ~0.09% — well below the unconditional 0.37% baseline.

Summary

Grade: A. Seventeen passing checks, one watch on inventory growth that directly reflects the NIKTIMVO and ZYNYZ launches.

Incyte runs one of the cleanest financial profiles in mid-cap biotech: 92.8% gross margin, essentially no debt, $3.58B of cash and short-term investments, FCF of $1.33B. The single watch flag on inventory growth is a textbook positive signal — inventory builds in advance of commercial launches that are actually happening, and the gross margin held flat at 92.8% with no margin-compression signs of obsolescence.

The real risk for Incyte is not earnings quality — it is the binary business risk that management itself identifies as the #1 risk factor: JAKAFI patent exclusivity expires in 2028. The company needs OPZELURA, NIKTIMVO, ZYNYZ and the pipeline to collectively replace a product contributing 60% of total revenue within three years. The financial strength disclosed in this 10-K gives management maximum runway to execute that transition — $3.58B of cash, no debt, $1.33B of annual FCF, and a high-margin operating model that throws off cash rapidly. The A grade reflects the financial health, not the strategic risk.

**Disclaimer**: This report is based on Incyte's FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K (Filed 2026-02-10) + Yahoo Finance

Auditor: Ernst & Young LLP (Unqualified opinion, 1 critical audit matter)